Trials / NCT07901751
Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT)
Recruiting now Phase 2 / Phase 3 Optogenetics, Gene therapy
- Sponsor
- Ray Therapeutics, Inc.
- Treatment
- RTx-015; Sham Control
- Gene
- Not gene-specific
- Conditions
- Retinitis Pigmentosa (RP), Inherited Retinal Diseases
- Ages
- 18 Years to no upper limit
- Enrollment
- 60 participants
- Started
- 2026-10
- Main results expected
- 2028-10
- Results posted
- Not yet
- Record last updated
- 2026-10-28
What the study is testing
The purpose of this clinical trial is to evaluate the effectiveness and safety of a single injection into the eye of an investigational gene therapy in participants with retinitis pigmentosa (RP).
Where it runs
United States (14)
- RayTx Clinical Site, Phoenix, Arizona (not yet recruiting)
- RayTx Clinical Site, Bakersfield, California (recruiting now)
- RayTx Clinical Site, Beverly Hills, California (recruiting now)
- RayTx Clinical Site, Santa Barbara, California (not yet recruiting)
- RayTx Clinical Site, Deerfield Beach, Florida (not yet recruiting)
- RayTx Clinical Site, ‘Aiea, Hawaii (not yet recruiting)
- RayTx Clinical Site, Oak Park, Illinois (recruiting now)
- RayTx Clinical Site, Detroit, Michigan (not yet recruiting)
- RayTx Clinical Site, Edina, Minnesota (not yet recruiting)
- RayTx Clinical Site, Bloomfield, New Jersey (not yet recruiting)
- RayTx Clinical Site, Greensboro, North Carolina (recruiting now)
- RayTx Clinical Site, Portland, Oregon (recruiting now)
- RayTx Clinical Site, Mt. Pleasant, South Carolina (recruiting now)
- RayTx Clinical Site, San Antonio, Texas (not yet recruiting)